Find a Provider

Katherine L. Nathanson, MD

Katherine L. Nathanson, MD Physician

Associate Professor of Genetics
Professor of Medicine

Languages spoken:

  • French

Dr. Nathanson is a Penn Medicine employed physician.

Clinical Specialties

Specialties:

  • Medicine
    • Medical Genetics

Programs & Services:

  • Cancer
    • Basser Center for BRCA
  • Medical Genetics

Board Certification:

  • Medical Genetics, 1999

Conditions & Treatments:

  • acoustic neuromas
  • Birt-Hogg-Dubé syndrome
  • cancer genetics
  • Genetic Counseling
  • genetic skin disease
  • Genetic Testing
  • hereditary cancer syndrome
  • hereditary papillary renal cancer
  • Klinefelter syndrome
  • Li-Fraumeni syndrome
  • medical genetics
  • Medical Genetics
  • neurofibromatosis
  • paragangliomas
  • pheocromocytoma/paragangliomas
  • schwannomatosis
  • tuberous sclerosis
  • von Hippel Lindau syndrome

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Beth Israel Deaconess Medical Center
Fellowship: Children's Hospital of Philadelphia

Memberships

American Association for Cancer Research, National American Association for the Advancement of Science, National American College of Medical Genetics, National American College of Physicians, National American Society for Clinical Investigation, National American Society for Human Genetics, National Breast Cancer Information Core Steering Committee, National Melanoma Research Breakthrough Consortium, National Movember GAP5 Translational Research Steering Committee (Testicular Cancer), International National Institutes of Health, Cancer Genetics Study Section, National National Institutes of Health, National Cancer Institute Loan Repayment Program Study Section, National National Institutes of Health, National Cancer Institute, National TCGA Pheochromocytoma/Paraganglioma Disease Working Group, National TCGA Testicular Germ Cell Tumor Working Group, National Cancer Institute, National Tuberous Sclerosis Alliance, National

Affiliation

Dr. Nathanson is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Research Interests:

Dr. Nathanson’s research focuses on the genetics of human cancer, both germline changes which confer susceptibility to cancer and somatic genetic changes associated with outcome.

Her research projects fall into several areas:

1) Identification and characterization of germline genetic changes associated with breast cancer susceptibility. These projects utilize two sample sets, a large clinical database of high risk breast cancer patients and a case-control study of white and black patients with breast cancer. Currently the projects in the laboratory focus on resequencing of BRCA1-associated genes as candidate breast cancer susceptibility genes in patients with high risk breast cancer and studying copy number variation as associated with potential susceptibility to high risk breast cancer in families with multiple cases of breast cancer.

2) Identification of genetic changes associated with testicular cancer susceptibility in case-control sample set. Dr. Nathanson recently completed a successful genome wide association study in testicular cancer, and is in the process of designing and doing a number of follow-up studies.

3) Identification of somatic genetic markers in melanoma as determinants of response to therapy. The projects in the laboratory focus on several aspects of melanoma genetics including genotyping patients to determine targeted therapy selection, using genetics and genomics to sub-set melanomas, as well as understand response to therapy, and identify novel genes important in melanoma progression.

Selected Publications:

Riff BP, Katona BW, Wilkerson M, Nathanson KL, Metz DC: HNPCC-Associated Pheochromocytoma: Expanding the Tumor Spectrum. Pancreas 44 (4): 676-678,2015.

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van : Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PloS One 10 (4): e0120020,2015.

Bradbury AR, Patrick-Miller LJ, Egleston BL, DiGiovanni L, Brower J, Harris D, Stevens EM, Maxwell KN, Kulkarni A, Chavez T, Brandt A, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM: Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genet Med : 2015.

Rebbeck TR, Mitra N, Wan F, Sinilnikova O, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, and the CIMBA Consortium: Association of Type and Location of BRCA1 and BRCA2 Mutations with Risk of Breast and Ovarian Cancer. JAMA 313 (13): 1347-1361,2015.

Academic Contact Info

351 BRB II/III
421 Curie Blvd
University of Pennsylvania

Philadelphia, PA 19104
Phone: (215) 662-4740
Patient appointments: 800-789-PENN (7366)

Related Links